Let's consider these excellent candidates: CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals (NASDAQ: VRTX), two innovative drugmakers. Here's why they are both buys heading into 2026.

To our immune system, a potentially lifesaving gene therapy can look a lot like a dangerous infection. That's because most ...

One of the practical applications of thinking long-term is to buy and hold exceptional stocks with strong growth prospects. Here are three brilliant growth stocks to buy now and hold for the long term ...

Discover why CLLS is a top speculative Buy, with promising CAR-T therapies, strong big pharma partnerships, and attractive ...

Using base-editing technology, the pioneering gene therapy (BE-CAR7), has been used to treat a previously untreatable type of ...

Shares of gene-editing company Intellia Therapeutics continue to struggle under significant pressure. This follows the U.S. Food and Drug Administration's (FDA) decision to halt the firm's most ...

In a study published in Genome Research, a team of researchers, including Cornell College Assistant Professor of Biology ...

Genetic risk models and variant classification tools are refining breast cancer risk assessment by identifying high-risk ...